Clinical trial · Observational
A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated Non-small Cell Lung Cancer (NSCLC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies. This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Overall survival (OS)
- timeFrame
- Up to 10 years.
- description
- Time from diagnosis to death.
- measure
- Duration of therapy (DOT)
- timeFrame
- Up to 10 years.
- description
- Time from start of treatment regimen to end of treatment regimen.
- measure
- Real-world progression-free survival (PFS)
- timeFrame
- Up to 10 years.
- description
- Time from start of treatment regimen to disease progression or death.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed advanced NSCLC 2. Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation 3. Diagnosis date from 1 Jan 2013 to 31 Dec 2024 (to allow for minimum 12 months of follow-up clinical and treatment outcome data) 4. Male or female adults, age as defined by local regulations Exclusion Criteria: 1\. Patients without an EGFR exon 20 insertion mutation
References
Publications (0)
Data not yet available